Floatz logo

Orelabrutinib

Primary Central Nervous System Lymphoma

The First Affiliated Hospital with Nanjing Medical UniversitySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Primary Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
(+)-VINCRISTINE
Ono Pharmaceutical Co., Ltd.
Phase 4BBB
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Inno-206
Juan P. Alderuccio, MD
Phase 4BB
Idarubicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB

View all 50 →

Same molecule, other indications

Orelabrutinib is also rated in:

marginal zone lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
mantle cell lymphomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →